- United States
- /
- Life Sciences
- /
- NasdaqGM:PSNL
Personalis (NASDAQ:PSNL) shareholder returns have been solid, earning 248% in 1 year
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! Take, for example Personalis, Inc. (NASDAQ:PSNL). Its share price is already up an impressive 248% in the last twelve months. It's even up 47% in the last week. Unfortunately the longer term returns are not so good, with the stock falling 63% in the last three years.
Since it's been a strong week for Personalis shareholders, let's have a look at trend of the longer term fundamentals.
Check out our latest analysis for Personalis
Because Personalis made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Over the last twelve months, Personalis' revenue grew by 24%. We respect that sort of growth, no doubt. While that revenue growth is pretty good the share price performance outshone it, with a lift of 248% as mentioned above. Given that the business has made good progress on the top line, it would be worth taking a look at its path to profitability. Of course, we are always cautious about succumbing to 'fear of missing out' when a stock has shot up strongly.
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
This free interactive report on Personalis' balance sheet strength is a great place to start, if you want to investigate the stock further.
A Different Perspective
It's nice to see that Personalis shareholders have received a total shareholder return of 248% over the last year. Notably the five-year annualised TSR loss of 8% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Personalis is showing 4 warning signs in our investment analysis , and 1 of those is potentially serious...
We will like Personalis better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:PSNL
Personalis
Develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific.
Excellent balance sheet slight.